Overview

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Status:
Recruiting

Trial end date:
2023-03-15

Target enrollment:

Participant gender:

Summary

This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).

Phase:

Phase 1

Details

Lead Sponsor:

Inhibrx, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies
Pembrolizumab